BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«G0 Phase

Below is an extended G0 Phase research listing. Click here to return to the G0 Phase main in depth entry.

Recent Publications on G0 Phase:

Coenzyme Q0 induces apoptosis and modulates the cell cycle in estrogen receptor negative breast cancer cells.
We postulated that methoxy-substituted cyclic compounds could inhibit...
Direct Link
3rd October, 2008
Department of Pharmacology and Toxicology, University of Otago, Dunedin,
[Regulation of cell-cycle exit and G0-phase maintenance during differentiation by Fbxw7] 1st October, 2008
E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Nutlin-3 is a selective inhibitor of the p53-Mdm2 interaction, and...
Direct Link
1st October, 2008
Helen Diller Family Comprehensive Cancer Center and Cancer Research
Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells.
p53 Is an important regulator of normal cell response to stress and...
Direct Link
1st October, 2008
Institute of Molecular and Cell Biology, University of Tartu, Tartu,
G0 cell cycle arrest alone is insufficient for enabling the repair of ionizing radiation-induced potentially lethal damage.
The repair of ionizing radiation-induced potentially lethal damage (PLD)...
Direct Link
17th September, 2008
Academic Medical Center, Laboratory for Experimental Oncology and
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.
Inhibitors of the enzyme 17alpha-hydroxylase/17,20 lyase are a new class...
Direct Link
16th September, 2008
Department of Pharmacology and Experimental Therapeutics, University of
Manganese chloride-induced G0/G1 and S phase arrest in A549 cells.
In the present study, we investigated the effects of manganese chloride...
Direct Link
13th September, 2008
Department of Toxicology, Peking University Health Science Center, Beijing
The search for cancer stem cells in hepatocellular carcinoma.
BACKGROUND: Recent evidence suggests that some solid cancers originate...
Direct Link
9th September, 2008
Department of Surgery, Medical Institute of Bioregulation, Kyushu
Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). 6th September, 2008
Laboratory of Immunology and Flow Cytometry Unit, National Institute on
IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes. 6th September, 2008
Immunology Division, Department of Pediatrics, University of Sherbrooke,
Cdh1: a master G0/G1 regulator.
APC/C(Cdh1) controls the G0 and G1 phases of the cell cycle. Using a...
Direct Link
5th August, 2008
Department of Pathology, NYU Cancer Institute, New York University School
Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells.
Poly(ADP-ribosyl)ation, catalysed by a family of poly(ADP-ribose)...
Direct Link
30th July, 2008
1Pasteur Institute-Fondazione Cenci Bolognetti, Department of Cellular
Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. 24th July, 2008
Clinical Experimental Oncology Laboratory, National Cancer Institute,
Effect of survivin regulation of transcription level by p21waf1 overexpression in HepG2 hepatocellular carcinoma cells.
The effect of cyclin-dependent kinase inhibitors Cip1/Waf1 (p21) on...
Direct Link
20th June, 2008
Department of Clinical Laboratory, Union Hospital, Tongji Medical College,
Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells.
We examined the mechanisms by which daidzein inhibits the growth of breast...
Direct Link
11th June, 2008
Plant Resources Research Institute, Duksung Women's University, 419
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional